SAN CARLOS, Calif., April 25 /PRNewswire-FirstCall/ -- Nuvelo, Inc. today announced that it will hold the following events in May:
Deutsche Bank Securities 31st Annual Health Care Conference
May 2, 2006
3:15 p.m. ET
Dr. Michael Levy, SVP Research & Development
http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=NUVO&item_id=1209156
First Quarter 2006 Financial Results and Accomplishments Conference Call & Webcast
May 5, 2006 11:30 a.m. ET (8:30 a.m. PT) Dr. Ted W. Love, Chairman & CEO Dr. Michael Levy, SVP, Research & Development Gary Titus, CFO & Chief Accounting Officer
Dial in: 800-706-7745 domestic and 617-614-3472 international with passcode 21460095
Replay: 888-286-8010 domestic and 617-801-6888 international with passcode 93591578, available through Friday, May 19, 2006
Webcast: www.nuvelo.com or visit the Thomson StreetEvents Network. Individual investors can listen to the call at www.earnings.com, Thomson's individual investor portal, powered by StreetEvents. Institutional investors can access the call via Thomson StreetEvents (www.streetevents.com), a password-protected event management site.
2006 Annual Shareholders Meeting May 24, 2006 2:00 p.m. ET (11:00 a.m. PT) Sofitel San Francisco Bay 223 Twin Dolphin Drive, Redwood City, CA 94065 If you plan to attend, please RSVP at ir@nuvelo.com.
Live audio webcasts of the events and presentations will also be available online via the Investor Relations portion of Nuvelo's website at www.nuvelo.com.
About Nuvelo
Nuvelo, Inc. is dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular and cancer therapy. Nuvelo's development pipeline includes three acute cardiovascular programs focused on alfimeprase, a direct-acting thrombolytic in Phase 3 clinical trials for the treatment of thrombotic- related disorders; rNAPc2, an anticoagulant that inhibits the factor VIIa and tissue factor protease complex that is currently in Phase 2 clinical development for acute coronary syndromes and a thrombin inhibiting aptamer for anticoagulation during medical procedures. Nuvelo is also progressing an emerging oncology pipeline which includes NU206, for the potential treatment of chemotherapy/radiation therapy-induced mucositis, as well as rNAPc2 for potential use as a cancer therapy. In addition, Nuvelo expects to leverage its expertise in secreted proteins and cancer antibody discovery to further expand its pipeline and create additional partnering and licensing opportunities.
Information about Nuvelo is available at our website at www.nuvelo.com or by phoning 650-517-8000.
Nuvelo, Inc.CONTACT: Nicole Estrin, Associate Director of Corporate Communications &IR, of Nuvelo, Inc., +1-650-517-8472, or nestrin@nuvelo.com
Web site: http://www.nuvelo.com//
